Instil Bio’s autologous cell therapy product manufactured from tumor-infiltrating lymphocytes has been granted FDA orphan designation as a treatment of stage IB2 to stage IV cervical cancer, according to a post to the agency’s website. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TIL:
- Instil Bio reports Q3 EPS (43c), consensus (44c)
- Society for Immunotherapy of Cancer to hold a meeting
- Instil Bio announces poster presentations of CoSTAR platform
- Instil Bio Pauses Clinical Trial Enrollments
- Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
